AU2011342378B2 - Thiosemicarbazone compounds and use in the treatment of cancer - Google Patents

Thiosemicarbazone compounds and use in the treatment of cancer Download PDF

Info

Publication number
AU2011342378B2
AU2011342378B2 AU2011342378A AU2011342378A AU2011342378B2 AU 2011342378 B2 AU2011342378 B2 AU 2011342378B2 AU 2011342378 A AU2011342378 A AU 2011342378A AU 2011342378 A AU2011342378 A AU 2011342378A AU 2011342378 B2 AU2011342378 B2 AU 2011342378B2
Authority
AU
Australia
Prior art keywords
cancer
compound
treatment
thiosemicarbazone
dp4cych4mt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011342378A
Other languages
English (en)
Other versions
AU2011342378A1 (en
Inventor
David B. Lovejoy
Des R. Richardson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010905539A external-priority patent/AU2010905539A0/en
Application filed by Individual filed Critical Individual
Priority to AU2011342378A priority Critical patent/AU2011342378B2/en
Publication of AU2011342378A1 publication Critical patent/AU2011342378A1/en
Application granted granted Critical
Publication of AU2011342378B2 publication Critical patent/AU2011342378B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU2011342378A 2010-12-17 2011-12-16 Thiosemicarbazone compounds and use in the treatment of cancer Ceased AU2011342378B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011342378A AU2011342378B2 (en) 2010-12-17 2011-12-16 Thiosemicarbazone compounds and use in the treatment of cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2010905539A AU2010905539A0 (en) 2010-12-17 Dipyridyl Thiosemicarbazone compounds and use in therapy
AU2010905539 2010-12-17
PCT/AU2011/001631 WO2012079128A1 (en) 2010-12-17 2011-12-16 Thiosemicarbazone compounds and use in the treatment of cancer
AU2011342378A AU2011342378B2 (en) 2010-12-17 2011-12-16 Thiosemicarbazone compounds and use in the treatment of cancer

Publications (2)

Publication Number Publication Date
AU2011342378A1 AU2011342378A1 (en) 2013-08-01
AU2011342378B2 true AU2011342378B2 (en) 2016-09-01

Family

ID=46243892

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011342378A Ceased AU2011342378B2 (en) 2010-12-17 2011-12-16 Thiosemicarbazone compounds and use in the treatment of cancer

Country Status (10)

Country Link
US (1) US8927580B2 (enExample)
EP (2) EP3287442A1 (enExample)
JP (1) JP5883457B2 (enExample)
KR (1) KR20140022786A (enExample)
CN (1) CN103370308B (enExample)
AU (1) AU2011342378B2 (enExample)
BR (1) BR112013015174A2 (enExample)
CA (1) CA2821984A1 (enExample)
NZ (1) NZ613085A (enExample)
WO (1) WO2012079128A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013015174A2 (pt) 2010-12-17 2020-08-11 Des R Richardson compostos de tio-semicarbazona e aplicação no tratamento de cancer
CA2892011A1 (en) * 2012-11-22 2014-05-30 Oncochel Therapeutics LLC Chemotherapy for drug-resistant cancer cells
CN104177288B (zh) * 2013-05-23 2020-05-01 中国人民解放军军事医学科学院毒物药物研究所 缩氨基硒脲衍生物及其药物组合物和用途
US12383518B2 (en) 2013-11-03 2025-08-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Disulfide-masked pro-chelator compositions and methods of use
US11504346B2 (en) 2013-11-03 2022-11-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Redox-activated pro-chelators
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
WO2017058748A1 (en) * 2015-09-29 2017-04-06 Oncochel Therapeutics, Llc Thiosemicarbazones
CN109052605A (zh) * 2018-07-26 2018-12-21 雷晓琳 一种重金属捕集剂及其制备方法
CN110698511B (zh) * 2019-11-15 2021-09-14 广西师范大学 以2-吡啶甲醛缩氨基硫脲为配体的锡配合物及其合成方法
KR102555030B1 (ko) * 2020-10-19 2023-07-14 고려대학교 산학협력단 티오세미카바존 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069801A1 (en) * 2003-02-05 2004-08-19 Unisearch Limited Metal ion chelators and therapeutic use thereof
CN1891701A (zh) * 2005-07-07 2007-01-10 桑迪亚医药技术（上海）有限责任公司 杂芳环缩氨基硫脲类化合物及其衍生物和它们在制备抗肿瘤药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4207400A1 (de) * 1992-03-09 1993-09-16 Bayer Ag Hydrazone
AU2003900495A0 (en) * 2003-02-05 2003-02-20 Unisearch Limited Aroylhydrazone derivatives and therapeutic uses thereof
WO2010000008A1 (en) * 2008-06-30 2010-01-07 Desi Raymond Richardson Thiosemicarbazone compounds and use thereof
BR112013015174A2 (pt) 2010-12-17 2020-08-11 Des R Richardson compostos de tio-semicarbazona e aplicação no tratamento de cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069801A1 (en) * 2003-02-05 2004-08-19 Unisearch Limited Metal ion chelators and therapeutic use thereof
CN1891701A (zh) * 2005-07-07 2007-01-10 桑迪亚医药技术（上海）有限责任公司 杂芳环缩氨基硫脲类化合物及其衍生物和它们在制备抗肿瘤药物中的应用

Also Published As

Publication number Publication date
CN103370308A (zh) 2013-10-23
EP2651894B1 (en) 2017-08-23
CA2821984A1 (en) 2012-06-21
CN103370308B (zh) 2015-06-17
AU2011342378A1 (en) 2013-08-01
NZ613085A (en) 2015-05-29
EP3287442A1 (en) 2018-02-28
BR112013015174A2 (pt) 2020-08-11
JP5883457B2 (ja) 2016-03-15
US20140206725A1 (en) 2014-07-24
EP2651894A4 (en) 2014-07-09
KR20140022786A (ko) 2014-02-25
US8927580B2 (en) 2015-01-06
WO2012079128A1 (en) 2012-06-21
EP2651894A1 (en) 2013-10-23
JP2014502599A (ja) 2014-02-03

Similar Documents

Publication Publication Date Title
US8927580B2 (en) Thiosemicarbazone compounds and use in the treatment of cancer
EP3600270B1 (en) Compounds and compositions for treating hematological disorders
JP6275153B2 (ja) ヘテロ環式グルタミナーゼ阻害剤
JP7033554B2 (ja) がんの併用療法
JP6666494B2 (ja) がんの処置のための医薬の組合せ
KR102375288B1 (ko) 대사항암제를 포함하는 항암용 조성물
HK1216297A1 (zh) 肿瘤溶解综合征的治疗药和预防药
JP6147246B2 (ja) Ａｋｔ及びｍｅｋ阻害剤化合物の組み合わせ、及び使用方法
US20210221805A1 (en) Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof
EP1608623B1 (en) Metal ion chelators and therapeutic use thereof
US20250248995A1 (en) Compositions and methods for treating polycythemia
JP2003506482A (ja) 癌の治療法
AU2005314252A1 (en) Compounds and methods for treating hemorrhagic fever viruses
WO2010000008A1 (en) Thiosemicarbazone compounds and use thereof
JP2019510084A (ja) 小分子型の活性酸素種誘導剤及びミトコンドリア活性阻害剤
WO2017058748A1 (en) Thiosemicarbazones
AU2004210010B2 (en) Metal ion chelators and therapeutic use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired